20.08
前日終値:
$19.59
開ける:
$20.32
24時間の取引高:
177.96K
Relative Volume:
0.54
時価総額:
$692.31M
収益:
$4.12M
当期純損益:
$-56.68M
株価収益率:
-3.6227
EPS:
-5.5429
ネットキャッシュフロー:
$-51.44M
1週間 パフォーマンス:
-6.82%
1か月 パフォーマンス:
+14.03%
6か月 パフォーマンス:
-27.46%
1年 パフォーマンス:
-17.33%
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
DNTH を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
DNTH
Dianthus Therapeutics Inc
|
20.08 | 692.31M | 4.12M | -56.68M | -51.44M | -5.5429 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-20 | 開始されました | TD Cowen | Buy |
2024-10-03 | 開始されました | Oppenheimer | Outperform |
2024-07-26 | 開始されました | Robert W. Baird | Outperform |
2024-06-27 | 開始されました | Cantor Fitzgerald | Overweight |
2024-05-16 | 開始されました | H.C. Wainwright | Buy |
2024-02-15 | 開始されました | Stifel | Buy |
2023-12-26 | 開始されました | Jefferies | Buy |
2023-11-22 | 開始されました | Wedbush | Outperform |
2023-10-30 | 開始されました | Guggenheim | Buy |
2023-09-28 | 開始されました | Raymond James | Outperform |
2022-08-25 | ダウングレード | Goldman | Buy → Neutral |
2022-01-06 | アップグレード | Goldman | Neutral → Buy |
2021-08-20 | 再開されました | Goldman | Neutral |
2021-08-03 | ダウングレード | JP Morgan | Overweight → Neutral |
2021-07-22 | 繰り返されました | B. Riley Securities | Buy |
2021-06-29 | 開始されました | Cantor Fitzgerald | Overweight |
2021-06-15 | 開始されました | BTIG Research | Buy |
2021-05-18 | 開始されました | B. Riley Securities | Buy |
2021-01-07 | 開始されました | Mizuho | Buy |
2020-06-08 | アップグレード | Goldman | Neutral → Buy |
2019-03-25 | ダウングレード | Goldman | Buy → Neutral |
2019-03-15 | 開始されました | Raymond James | Outperform |
すべてを表示
Dianthus Therapeutics Inc (DNTH) 最新ニュース
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results - The Manila Times
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Lifted by Braidwell LP - MarketBeat
Avidity Partners Management LP Lowers Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - MSN
106,434 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Bought by Ally Bridge Group NY LLC - MarketBeat
5AM Venture Management LLC Sells 203,908 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Wells Fargo & Company MN Sells 8,271 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Allostery Investments LP Buys New Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $54.33 - MarketBeat
Barclays PLC Raises Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
180,000 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Acquired by Adage Capital Partners GP L.L.C. - MarketBeat
Dianthus Therapeutics completes enrollment for MaGic trial - Investing.com Australia
Dianthus Therapeutics completes enrollment for MaGic trial By Investing.com - Investing.com Canada
Dianthus (DNTH) Completes Enrollment for Phase 2 MaGic Trial | D - GuruFocus
Dianthus Therapeutics Inc expected to post a loss of 85 cents a shareEarnings Preview - TradingView
Breakthrough gMG Treatment DNTH103 Hits Major Milestone: Phase 2 Results Coming This Fall - Stock Titan
Invesco Ltd. Purchases 790 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
TCG Crossover Management LLC Takes Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
JPMorgan Chase & Co. Increases Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap DownHere's What Happened - MarketBeat
Legal & General Group Plc Buys 2,363 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
BlackRock, Inc. Reduces Stake in Dianthus Therapeutics Inc. - GuruFocus
Dianthus Therapeutics to Participate in Two Upcoming Investor Events - The Manila Times
Dianthus Therapeutics Reveals Growth Strategy at Two Elite Healthcare Investment Forums - Stock Titan
Dianthus Therapeutics (DNTH) Sees Rise in Short Interest Despite Stock Rebound | DNTH Stock News - GuruFocus
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.4%Time to Buy? - MarketBeat
Bain Capital Life Sciences Investors LLC Sells 323,716 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Walleye Capital LLC Purchases 52,890 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead - Seeking Alpha
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Bought by Geode Capital Management LLC - Defense World
Fmr LLC Purchases 36,133 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Vanguard Group Inc. Sells 20,331 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
A stock that deserves closer examination: Dianthus Therapeutics Inc (DNTH) - uspostnews.com
Dianthus Therapeutics Inc (DNTH) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):